The aim of this study was to determine whether the burden of JAK2 V617F allele correlated with major clinical outcomes in patients with polycythemia vera (PV). To this end, we determined JAK2 mutant allele levels in granulocytes of 173 PV patients at diagnosis. The mean (7s.d.) mutant allele burden was 52% (729); 32 patients (18%) had greater than 75% mutant allele. The burden of JAK2 V617F allele correlated with measurements of stimulated erythropoiesis (higher hematocrit, lower mean cell volume, serum ferritin and erythropoietin levels) and myelopoiesis (higher white cell count, neutrophil count and serum lactate dehydrogenase) and with markers of neutrophil activation (elevated leukocyte alkaline phosphatase and PRV-1 expression). As compared to those with less than 25% mutant allele, patients harboring greater than 75% JAK2 V617F allele were at higher relative risk (RR) of presenting larger spleen (RR 4.7; Po0.001) or suffering from pruritus (RR 3.1; Po0.001). In these patients, the risk of requiring chemotherapy (RR 1.8; P ¼ 0.001) or developing major cardiovascular events (RR 7.1; P ¼ 0.003) during follow up were significantly increased. We conclude that a burden of JAK2 V617F allele greater than 75% at diagnosis points to PV patients with high-risk disease.
Introduction
The clinical course of patients with polycythemia vera (PV), one of the Philadelphia (Ph) chromosome-negative chronic myeloproliferative disorders (CMPD), 1, 2 is marked by an increased rate of arterial and venous thrombosis, 3 which represent the major cause of illness and death in untreated patients, 4 and accounted for 45% of all deaths in the cohort of patients enrolled in the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) study. 3 Age older than 65 years and previous history of thrombosis are the most important prognostic factors, which allowed to identify groups of patients in whom the rate of thrombosis increased from 2.5 ('low-risk') to 10.9 ('high-risk') events per 100 persons per year. 3 Less frequently, the disease evolves to post-polycythemic myelofibrosis or transforms to acute myeloid leukemia, 5 which accounted for 13% of fatal cases. 3 A major advancement in understanding the pathogenesis of PV has been the discovery of an acquired mutation occurring in the negative regulatory pseudo-kinase JH2 domain of Janus kinase 2 (JAK2 V617F ). [6] [7] [8] [9] JAK2 is a cytoplasmic tyrosine kinase, which promotes the intracellular signaling cascade originating from ligand engagement of homodimeric type I cytokine receptors, such as the erythropoietin receptor. The mutation results in a 'gain-of-function' of JAK2, which is constitutively phosphorylated and activated. 10 Erythroid progenitors harboring JAK2 V617F mutation are hypersensitive to erythropoietin, and this accounts for the phenomenon of erythropoietin-independent colonies that was discovered more than 30 years ago. 11, 12 Studies of purified hematopoietic progenitors have demonstrated that the expanded stem cell compartment in PV is preferentially shifted towards the erythroid differentiation pathway. 13 Finally, mice expressing JAK2 V617F by means of retroviral vector develop a myeloproliferative disease, which recapitulates the features of PV. 8, [14] [15] [16] The JAK2 V617F mutation has been demonstrated in the majority of patients with PV, making it a formidable diagnostic tool in the differential diagnosis with secondary erythrocytosis. [17] [18] [19] However, it is not specific for PV, since 50-70% of patients with essential thrombocythemia (ET) or primary myelofibrosis harbor JAK2 V617F mutation. 2 As a result of mitotic recombination affecting chromosome 9p. 20 with duplication of mutant allele, D30% of patients with PV are JAK2 V617F homozygous. [6] [7] [8] [9] Homozygosity may have profound effect on cell phenotype, as reflected by extent of changes in the expression of downstream target genes as compared to heterozygous cells. 21, 22 However, at the progenitor cell level, it was found that most PV patients, unlike very few with ET, have variable proportion of mixed homozygous, heterozygous and wild-type progenitors, even though patients were considered heterozygous when analysis had been performed in granulocyte samples as for routine genotyping. 23, 24 Therefore, definition of homozygosity, as it is currently used in the diagnostic setting, should be intended only in the sense that ratio of mutant to wildtype JAK2 allele in granulocytes is greater than 0.51. Finally, novel mutations in exon 12 of JAK2 have been recently discovered in the few JAK2 V617F -negative patients with a diagnosis of PV or idiopathic erythrocytosis; 25 the resulting phenotype is different from that of classic PV under several respects. 25 In contrast, it is still largely under debate whether, and how, the presence of JAK2 V617F mutation influences disease phenotype in PV patients. Most of the published studies involved small series, often considering patients with the different CMPD all together, and all had a retrospective design. In the largest of these, which collected 323 PV patients from 12 Italian centers, the clinical characteristics of 219 heterozygous and 104 homozygous patients were compared. 26 It was found that homozygous patients had both laboratory (higher hematocrit and leukocyte count) and clinical (more frequent splenomegaly, greater need of chemotherapy) features that suggested an influence of mutant allele burden on disease presentation, although no significant difference was found as concerned with the rate of major cardiovascular events. Similar findings had been reported in a smaller series by Tefferi et al. 27 In view of this background, we reasoned that conflicting results concerning the influence of mutational state on disease phenotype might have been due to both the retrospective design of the studies and the use of qualitative, rather than quantitative, assays for determining the relative contribution of mutant and wild-type JAK2 alleles. Therefore, in this study, we employed quantitative assays for V617F allele in a prospective series of PV patients, who were genotyped at diagnosis, with the aim to determine how the burden of JAK2 mutant allele correlated with laboratory and clinical features of the disease at presentation and whether it was able to predict for major clinical outcomes in the follow up.
Patients and methods

Study patients
PV was diagnosed on the basis of criteria established by the World Health Organization. 28 Patients were eligible to enter the study if they had donated a blood sample at the time of diagnosis or within the following 6 months. When blood was sampled, no patient had received yet a specific treatment for PV, although most of them were already on low-dose aspirin. All diagnoses were re-evaluated using original clinical records and bone marrow biopsies by an ad hoc panel of four hematologists and two pathologists who were blinded to the results of JAK2 genotyping. Rules for collection, storage and use of blood samples were approved by Local Institutional Review Board and all subjects had provided written informed consent.
Study aims
Our first aim was to determine possible correlations between the burden of JAK2 mutant allele, measured at diagnosis, and laboratory parameters (hematocrit, leukocyte or platelet count, serum lactate dehydrogenase (LDH) levels, leukocyte alkaline phosphatase (LAP) and serum erythropoietin levels) or clinical features (splenomegaly, aquagenic pruritus and systemic symptoms), which were evaluated concurrently with blood sampling. We also aimed at prospectively determining the correlation between V617F allele burden and rate of major clinical events during follow-up; these included arterial and venous thrombosis, major hemorrhages, use of cytoreductive drugs, evolution to myelofibrosis or transformation to acute leukemia.
Determination of JAK2
V617F allele burden
Peripheral blood granulocytes were separated by differential centrifugation over a Ficoll-Paque gradient, and contaminating red cells were removed by hypotonic lysis; cell pellets were either re-suspended in Trizol (Invitrogen SRL, Milano, Italy) for RNA extraction or processed for DNA isolation with the QIAmp DNA blood Kit (Qiagen, GmbH, Germany). DNA and RNA were quantified with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technology Wilmington, DE, USA). Complementary DNA (cDNA) was reverse transcribed from 1.0 mg RNA with random hexamers and MuLV reverse transcriptase (Applied Biosystems, Foster City, CA, USA). Quantification of JAK2 V617F allele burden was performed employing two independent methods. The first was an amplification-refractory mutation sequencing polymerase chain reaction (ARMS-PCR), which amplifies cDNA obtained by retrotranscription of granulocyte RNA. 29 The second was a quantitative real-time PCR assay (QRT-PCR), which employs genomic DNA from the same cell source. 30 All samples were routinely genotyped for JAK2 V617F mutation also using an allele-specific oligonucleotide (ASO)-PCR assay, using 75 ng granulocyte DNA, followed by digestion of PCR products with BsaXI restriction enzyme (New England Biolabs, Hitchin, UK), as described. 6 In case of the ARMS-PCR procedure, 29 both wild-type and mutation-specific primer were labeled with 5-FAM to permit resolution and quantification of amplicons after capillary electrophoresis in an ABI PRISM 3100 analyzer (Applied Biosystems). Amplification was performed at 621C using AmpliTaq Gold DNA polymerase (Applied Biosystems), starting from 50 ng cDNA, for a total of 27 cycles, which is in the linear range of procedure.
29 JAK2 V617F allele burden was expressed as percent ratio of JAK2 V617F and (JAK2 WT þ JAK2 V617F ) integrated peak areas, as described. 29 The method has a sensitivity of D0.1% mutant allele. 29 For QRT-PCR assay, 30 we used 20 ng of genomic DNA. PCR amplification and detection were performed on an ABI Prism 7300 analyzer (Applied Biosystems) with an initial step of 10 min at 951C, 40 cycles of 15 s at 951C and 1 min at 601C, using the Taqman PCR reagent kit (Applied Biosystems). Primers flanking the mutant region (forward primer:
0 ) were employed together with Taqman probes which were specific for either wild-
All samples were analyzed in triplicate and the amount of JAK2 V617F allele was calculated by comparison with serial dilutions of mutant and wild-type DNA (Supplementary Figure 1) ; mutant DNA was obtained from a PV patient harboring 100% mutant allele as evaluated by both direct sequencing and ARMS assay. The mean of triplicate DC T determinations (C T JAK2V617F -C T JAK2WT ) was used to calculate the percentage of mutant allele. Estimated assay sensitivity was D2%. Positive and negative controls were included in each assay. The results obtained with ARMS and QRT-PCR assays on the same granulocyte sample were found to be significantly correlated, as shown in Supplementary Figure 2 . Eighty percent of the samples were analyzed using both assays, and the mean of the individual values obtained with each techniques was used; the remaining twenty percent of samples were analyzed using QRT-PCR assay only.
Definition of outcome events
Pruritus was recorded when it was described by the patient as diffuse, non-occasional, itching exacerbated by water contact. Systemic symptoms included loss of 10% or more of body weight in the last 6 months, night sweating or pronounced asthenia. Splenomegaly was defined on the basis of an ultrasound scan reporting a measurement of the spleen longitudinal diameter; patients with splenomegaly (defined as those with spleen longitudinal diameter greater than 12 cm) were further divided into two groups on the basis of their spleen size (12-15 cm or greater than 15 cm, respectively). Major cardiovascular events were registered only if they developed after diagnosis or had occurred in the 2 preceding years. 4 Since there was no death attributable to cardiovascular causes, we report here only the definitions concerning nonfatal events. Nonfatal acute myocardial infarction was defined when at least two of the following were present: chest pain of typical duration and intensity; increase of the levels of cardiac enzymes of at least twofold; ST-segment elevation or depression of at least 1 mm in any limb lead of the electrocardiogram, or of at least 2 mm in any precordial lead, or both. Nonfatal stroke was defined in the presence of unequivocal signs or symptoms of a neurologic defect, of sudden onset and of more than 24 h duration; the diagnosis also required computer tomography, magnetic resonance imaging or any other objective means to confirm diagnosis. Transient ischemic attacks were considered in the presence of the following signs and symptoms: abrupt onset of unilateral motor or sensory disturbances, speech defect, constructional apraxia, homonymous hemianopsia or transient monocular blindness involving the entire, or localized portions of the visual field that resolved completely within 24 h. However, transient ischemic attacks were registered in the study only in the presence of unequivocal hospital records. Deep venous thrombosis was defined by the appearance of typical clinical signs, which had to be confirmed by at least one objective technique including ultrasonography, phlebography, impedance plethysmography or computed tomography in case of unusual sites, especially in the splenic, hepatic, portal or mesenteric vessels. Diagnosis of pulmonary embolism required a positive pulmonary angiogram, or a ventilation-perfusion scan or computed tomography highly suggestive of pulmonary embolism.
Bleeding was considered in the case of major events, that were either fatal episodes, intracranial bleeding or any other hemorrhage, which led to hospitalization and/or caused hemoglobin reduction greater than 2 g/dl and/or required transfusion of at least 2 red blood cell units.
For the purposes of this study, treatment was considered in case the patient received cytoreductive drugs, either as the sole therapy or in association with phlebotomy. Treatment was instituted by the referring physician based on current practice and recommendations 31, 32 and in any case independently of the knowledge of JAK2 genotype; reasons for chemoreduction were high-risk condition, poor compliance to, or partial ineffectiveness of, phlebotomy, progressive leukocytosis, thrombocytosis or spleen enlargement 31, 32 Unless in the presence of specific contraindications or of side effects, all patients were maintained on prophylactic low-dose aspirin. 33 
Statistical analysis
The JAK2 mutant allele burden was considered both as a continuous variable and as an ordered categorical variable based on the following groups: 1-25%, greater than 25% but not more than 50%; greater than 50% but no more than 75% and greater than 75% JAK2 V617F allele. We used the w 2 or Fisher's exact test (2 Â 2 table) or w 2 test for trend (larger contingency table), where appropriate, to compare categorical variables among the groups that had been categorized according to mutation load. Analysis of continuous variables among the groups was performed using the MannWhitney U test (two groups) or Kruskal-Wallis test with the use of Dunn's method for multiple comparison. The analysis of correlation between JAK2 V617F allele burden and hematologic parameters was performed according to Spearman's rank nonparametric correlation test. To calculate unadjusted relative risk (RR) and the 95% confidence interval (CI), we used the group of patients having 1-25% mutant allele load as the reference population. Kaplan-Meier analysis and the log-rank test were used to estimate cytoreduction-free survival. Unconditional logistic regression models with backward stepwise were used to identify the factors that were associated with increased probability of receiving chemotherapy or having thrombotic events; age, sex, hematocrit, white cell count, platelet count, LDH, JAK2
V617F allele load and splenomegaly were used as covariates.
A P-value of less than 0.05 was considered to indicate statistical significance; all tests were two-tailed. Data were PRV-1 overexpression was defined in the presence of a PRV-1/ GAPDH C T ratio equal or less than 1.17, as described previously. 34 Total number of patients evaluated was 135.
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V617F allele burden and clinical outcome in polycythemia vera AM Vannucchi et al 80 100 Figure 1 The correlation between JAK2 V617F allele burden and hematologic parameters in the 173 patients with PV. V617F allele burden and a number of laboratory parameters were concurrently determined in peripheral blood samples obtained at diagnosis. The parameters of the regression, and the significance value, are shown inside each plot. PV, polycythemia vera.
V617F allele burden and clinical outcome in polycythemia vera AM Vannucchi et al processed using the SPSS (Statsoft Inc., Tulsa, OK, USA) software. Table 1 summarizes clinical and laboratory features at diagnosis in the 173 patients with PV considered in the study, and the major clinical events that occurred during follow-up. Twentytwo patients had been included in a previous collaborative multicenter retrospective study. 26 Median follow-up was 24 months, with 93% of the patients being followed for 4 years from diagnosis. At presentation, 17 patients (10%) referred a cardiovascular event, while 16 patients (9%) developed thrombosis during follow-up; in 11 patients one or more recurrence of thrombosis occurred. Total number of cardiovascular events was 46, of which 32 were arterial and 14 were venous thrombosis; for statistical analysis, we considered only the first cardiovascular event for each patient. A minority of patients (6%) presented hemorrhages, mainly during follow-up. One patient evolved to myelofibrosis and one to acute myeloid leukemia.
Results
Patient characteristics
Median JAK2 V617F mutant allele burden was 52.9729.3%; patients were categorized into four groups according to the amount of JAK2 mutant allele (Table 1) . Thirty-eight percent of the patients had JAK2 mutant allele burden greater than 50%; this value is higher than reported estimates of JAK2 V617F homozygosity employing qualitative assays (D30%) [6] [7] [8] [9] and should be likely ascribed to higher sensitivity of quantitative assays employed in this study. We found no correlation between burden of JAK2 V617F allele and patient age, while females were preferentially distributed in the highest JAK2 V617F allele classes ( Table 2) .
Correlation of JAK2 V617F allele burden with laboratory features
We found that burden of JAK2 V617F allele was directly correlated with abnormally increased levels of hematocrit, white cell and neutrophil count, LDH and LAP; on the contrary, the mean cell volume, serum erythropoietin and serum ferritin levels decreased progressively ( Figure 1 and Table 2 ). Platelet count was lower in patients presenting the highest JAK2 V617F allele burden, although it did not reach the significance level. We also observed that RNA levels of polycythemia-rubra vera-1 (PRV-1) gene, which is known to be abnormally regulated in granulocytes of patients with PV, 34 were correlated with mutant allele burden ( Table 2) ; using linear regression analysis, the correlation factor was r ¼ À0.87 (Po0.001) (not shown in detail).
Correlation of JAK2 V617F allele burden with clinical features
We found that JAK2 V617F allele burden correlated with a progressively higher RR of presenting aquagenic pruritus compared to the 1-25% allele group used as reference population: RR was 2.2 (95% CI, 1.1-6.4, P ¼ 0.058) in the 50-75% group and 4.2 (95% CI. 2.2-7.9, Po0.001) in patients with greater than 75% mutant allele (Figure 2a) . On the contrary, systemic symptoms were unaffected by extent of JAK2 V617F burden (Figure 2b ). There was also a significant Figure 2 Effect of JAK2 V617F allele burden on the risk of pruritus, systemic symptoms and splenomegaly in various patient categories. The analysis was performed to calculate the relative risk (RR) of a patient with polycythemia vera to suffer from aquagenic pruritus (a), to complaint of systemic symptoms (b), or to present splenomegaly (considered as a spleen longitudinal diameter greater than 12 cm (c) or greater than 15 cm (d) on ultrasonography) according to the amount of JAK2 mutant allele measured at diagnosis. Reference category were patients with 1-25% mutant allele. Squares indicate RR along with the 95% confidence interval (CI; vertical bars); when the upper CI was greater than 8, the value was reported within parenthesis. In the category of patients with greater than 75% allele burden, statistical significance was Po0.01 for pruritus, P ¼ 0.86 for systemic symptoms, Po0.001 for splenomegaly, and Po0.001 for spleen with a longitudinal diameter greater than 15 cm. In the latter case, the 50-75% group also had significantly greater RR (P ¼ 0.008) in comparison to reference group.
JAK2
V617F allele burden and clinical outcome in polycythemia vera AM Vannucchi et al correlation between JAK2 V617F allele burden and proportion of subjects presenting splenomegaly, with an RR of 1.7 (95% CI, 1.2-2.6, Po0.001) in patients who had greater than 75% mutant allele ( Figure 2c) ; furthermore, the RR of having a spleen longitudinal diameter greater than 15 cm was 2.7 (95% CI, 1.2-9.8, P ¼ 0.008) and 4.7 (95% CI, 1.8-12, Po0.001) in patients with mutant allele burden from 50 to 75% or greater than 75%, respectively (Figure 2d) .
Patients with cardiovascular events (either at diagnosis or during follow-up) progressively increased from 10, 14, 24 to 37% in the different groups according to categorized JAK2 V617F allele burden (P ¼ 0.001 using w 2 test for trend). Accordingly, the RR of total thrombosis was 3.56-fold higher (95% CI, 1.47-7.1) in patients having greater than 75% mutant allele compared to reference population (P ¼ 0.004) (Figure 3a) . Mutant allele burden did not impact on thrombosis at the time of diagnosis (Figure 3b) , while the RR of thrombosis during follow-up was significantly increased in patients having greater than 75% mutant allele (RR 7.1 (95% CI, 1.6-10.1), P ¼ 0.003) (Figure 3c ). Factors associated with thrombosis were age (P ¼ 0.027), previous thrombosis (P ¼ 0.041), leukocytosis 35 (P ¼ 0.047) and mutant allele burden (P ¼ 0.014); however, in multivariate analysis, the variable that maintained a significant association with cardiovascular events was represented by JAK2 V617F allele burden (P ¼ 0.039).
Forty-one percent of the patients at the time of diagnosis were already assuming low-dose aspirin; they accounted for 39, 43, 45 and 37% of patients included in the four quartiles, with no statistical difference among them. Fifty-one percent of the patients required cytoreductive drugs, in association with or without phlebotomy, for the control of disease. The proportion of patients treated with chemotherapy increased from 44% in the reference group to 46, 53 and 78% according to categorized JAK2 V617F allele burden (Po0.001, w 2 test for trend). Patients harboring greater than 75% mutant allele had significantly increased RR of cytoreduction (RR 1.8; 95% CI, 1.3-2.8; P ¼ 0.001) (Figure 4a ). Kaplan-Meier estimate indicated that at 12 months after diagnosis, 50% of patients harboring greater than 75% allele were already on chemotherapy as compared to V617F allele burden on the risk of cardiovascular events. The analysis was performed to calculate the RR of a patient with polycythemia vera to suffer from major cardiovascular events. Reference category were patients with 1-25% mutant allele. Squares indicate RR along with the 95% confidence interval (CI; vertical bars). Patients harboring greater than 75% JAK2 V617F allele had significantly increased RR of total thrombosis (at diagnosis and in the follow-up) (P ¼ 0.004; a) and of thrombosis occurring during follow-up (P ¼ 0.003, c), while the difference did not reach the significance levels for thrombosis occurring at diagnosis (b). RR, relative risk.
Figure 4 Effect of JAK2
V617F allele burden on the risk of receiving chemotherapy. The relative risk of receiving chemotherapy, according to the burden of JAK2 mutant allele at diagnosis, is presented in (a). Reference category were patients with 1-25% mutant allele. Squares indicate relative risk along with the 95% confidence interval (CI; vertical bars). Statistical significance value for the group of patients with greater than 75% mutant allele was P ¼ 0.001 in comparison with reference group. Time-dependent probability of survival free of cytoreductive therapy, according to categorized JAK2 V617F allele burden, is shown in (b). The statistical significance calculated with the log-rank test was Po0.001.
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V617F allele burden and clinical outcome in polycythemia vera AM Vannucchi et al less than 25% in all other groups (Po0.001; Figure 4b) . In multivariate analysis, that included patient age, sex, hematocrit, white cell count, platelet count, serum LDH and JAK2 V617F allele amount (as continuous variables) and splenomegaly (as discontinuous variable), JAK2 mutant allele burden was independently associated with the need of chemotherapy (Po0.001).
Discussion
PV is a heterogeneous disorder. While most patients have a smooth disease, others suffer from the complications associated with abnormal proliferation of hematopoietic cells, from an increased rate of cardiovascular events or from transformation to myelofibrosis or acute leukemia. This wide range of phenotypic presentation and outcome imposes a significant challenge for patient management, which varies from prevention of thrombotic events with phlebotomy, chemotherapy and low-dose aspirin, to symptomatic control of myeloproliferation. Stratification of patients according to risk would permit to tailor treatment and minimize exposure to cytoreductive drugs, which are questioned about their potential to favor malignant transformation. 5 Therefore, current therapeutic recommendations indicate chemotherapy in patients considered at 'high risk' for cardiovascular events because of age and history of thrombosis. 31 However, as a matter of fact, median age of patients with PV is around 65 years, and at least half of thrombosis that develop after diagnosis occur de novo.
We report here that the burden of JAK2 V617F allele influences disease phenotype and associates with most relevant outcomes in PV. Two sensitive amplification techniques were concurrently employed for quantification of JAK2 V617F allele burden in granulocytes, and their results were cross-validated. We found that a JAK2 mutant allele burden greater than 75% at diagnosis pointed to a category of patients with more symptomatic disease because of pronounced myeloproliferation and significantly increased rate of cardiovascular events and chemotherapy need during follow-up. On the other hand, the low number of patients who presented major hemorrhages or malignant transformation prevented us from drawing any inference as to whether mutant allele burden would predict also for these events. In addition, the relatively short follow-up did not allow us to assess the impact of JAK2 V617F allele burden on overall survival, which in these patients is greater than 10 years.
Results of this study support the view that heterogeneity of clinical manifestations in PV reflects the patient-to-patient variable degree of expansion of clonal hematopoietic cells that harbor JAK2
V617F allele, to the detriment of normal hematopoiesis. This could be inferred by significant correlation existing between mutant allele burden and laboratory parameters that indicate stimulated erythropoiesis or granulopoiesis, as well as with markers of granulocyte activation. It is worthwhile that clinical improvements described in PV patients treated with recombinant interferon-a therapy, which included reduction of phlebotomy rate, of splenomegaly and of thrombo-hemorrhagic events, 36 were accompanied in one study by progressive decrease of JAK2 V617F allele amount in granulocytes. 37 Accurate determination of JAK2 V617F allele burden using quantitative assay, rather than merely defining heterozygosity versus homozygosity, and the fact that analysis was done at diagnosis rather than at variable times thereafter has been critical for better assessment of the prognostic role of JAK2
V617F
allele. This has overcome the biases associated with previous studies that involved qualitative assays and heterogeneous patient series, and that led to conflicting results on the clinical significance of JAK2 V617F mutation in PV. 6, 7, 9, 26, 27 In particular, we have been able to identify the category of patients having greater than 75% mutant allele as characterized by a significantly increased risk of major cardiovascular events during the following up; this correlation was missed in previous studies where homozygous patients were considered all together, as it could be evinced by the fact that patients included in the 50-75% quartile in this analysis did not present appreciable increase in thrombosis rate when compared to the reference group. The independent predictive role of greater than 75% JAK2 mutant allele burden was maintained after elimination of potential confounders in multivariate analysis, that included established risk factors for thrombosis such as age, previous thrombosis and leukocytosis. Recently, data partially conflicting with our own have been reported, 38 but the retrospective nature of that study, and the fact that bone marrow cells rather than purified granulocytes were used for V617F allele quantification, make hardly comparable the results.
Overall, quantification of JAK2 V617F allele burden might represent a novel, powerful way to stratify PV patients for their risk of cardiovascular events; as such, it might contribute to modify therapeutic approach particularly in younger patients who are thrombosis-free at diagnosis but conversely harbor high mutant allele burden. While definite clarification of this important issue will require larger prospective trial, in the meanwhile we would suggest that quantification of JAK2 V617F allele burden in PV might be conveniently employed for patient stratification, especially in case of future trials dealing with novel inhibitors of JAK2 kinase.
